Drug
Idelalisib clinical trials
Also written GS-1101, Zydelig® and CAL-101.
- studies test it
- 47
- open now
- 2
- in phase 3
- 9
- first study started
- 2008
Keep track of what changes. Save the idelalisib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Zydelig®
- 31
Studies by the year they started
47 studies that test it; most in 2015 (8)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 6 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 8 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 25
- Phase 3
- 9
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 29 · Other 18
Gilead Sciences (25) · Alliance for Clinical Trials in Oncology (2) · Dana-Farber Cancer Institute (2) · OHSU Knight Cancer Institute (2) · Calluna Pharma AS (1) · Mayo Clinic (1) · University of Maryland, Baltimore (1) · German CLL Study Group (1)
Often tested with
Tested in the same studies.
Rituximab (5) · Pembrolizumab (4) · Obinutuzumab (3) · Venetoclax (3) · Dasatinib (3) · Ruxolitinib (3) · Ibrutinib (2) · Everolimus (2)
Studies
Open first, then newest update. How each study uses idelalisib is read from its arms, and is right about nine times in ten.
Testing it · 47
- A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingPhase 4Eli Lilly and CompanyNCT07218341Written as Idelalisib
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingPhase 2Oslo University HospitalNCT05725200Written as Idelalisib
- Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasCompletedPhase 2Mayo ClinicNCT02332980Written as Idelalisib
- Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedPhase 1Alliance for Clinical Trials in OncologyNCT01838434Written as idelalisib
- Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular LymphomaCompletedPhase 1Alliance for Clinical Trials in OncologyNCT01644799Written as idelalisib
- A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary FibrosisActive, not recruitingPhase 2Calluna Pharma ASNCT06736990Written as CAL101
- A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLCompletedPhase 2Dana-Farber Cancer InstituteNCT02135133Written as Idelalisib
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell TransplantationCompletedPhase 2University of Maryland, BaltimoreNCT03133221Written as Zydelig
- Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular LymphomaTerminatedPhase 2Fondazione Italiana Linfomi - ETSNCT03890289Written as Idelalisib
- Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)CompletedPhase 2German CLL Study GroupNCT02445131Written as CAL-101
- Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived MalignanciesTerminatedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03151057Written as Idelalisib 100 MG
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524Written as Idelalisib
- Pembrolizumab + Idelalisib for Lung Cancer StudyTerminatedPhase 1/2Asha NayakNCT03257722Written as Idelalisib
- Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's MacroglobulinemiaCompletedPhase 2French Innovative Leukemia OrganisationNCT02962401Written as Idelalisib
- Dose Optimization Study of Idelalisib in Follicular LymphomaTerminatedPhase 3Gilead SciencesNCT02536300Written as Idelalisib
- Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKiCompletedPhase 2MorphoSys AGNCT02639910Written as Idelalisib
- Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTerminatedPhase 2OHSU Knight Cancer InstituteNCT01620216Written as Idelalisib
- Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell LymphomaCompletedPhase 2Nordic Lymphoma GroupNCT03576443Written as Idelalisib
- REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic LeukemiaTerminatedPhase 1/2PETHEMA FoundationNCT03742323Written as Idelalisib
- Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)CompletedPhase 1Gilead SciencesNCT02242045Written as Idelalisib
See all 47 studies that test idelalisib →
Given in every arm · 6 — idelalisib is usual care beside what is tested
- ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLLActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT02787369Written as Idelalisib
- Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell MalignanciesTerminatedPhase 1Gilead SciencesNCT02457598Written as Idelalisib
- Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedPhase 2Gilead SciencesNCT02968563Written as Idelalisib
- Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal AdenocarcinomaTerminatedPhase 1Gilead SciencesNCT02468557Written as Idelalisib
- Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic LeukemiaCompletedPhase 1Gilead SciencesNCT01088048Written as Idelalisib
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaCompletedPhase 1OHSU Knight Cancer InstituteNCT02779283Written as Idelalisib
As the comparator · 6 — what is tested is compared with idelalisib
- A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsRecruitingPhase 3BeOne MedicinesNCT06846671Written as Idelalisib
- A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)RecruitingPhase 3Dizal PharmaceuticalsNCT07139873Written as Idelalisib
- A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLActive, not recruitingPhase 3Acerta Pharma BVNCT02970318Written as Idelalisib
- Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingPhase 3Loxo Oncology, Inc.NCT04666038Written as Idelalisib
- A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i TherapiesWithdrawnPhase 3Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06205290Written as Idelalisib
- Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular LymphomaTerminatedPhase 2ADC Therapeutics S.A.NCT04699461Written as Idelalisib
Codes
What other systems call idelalisib · ClinicalTrials.gg INT005724
- MeSH (NLM) C552946idelalisibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) YG57I8T5M0IDELALISIBConfirmed FDA, NLM, Wikidata
- RxNorm 1544460Confirmed FDA, Wikidata
- Wikidata Q5908266idelalisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78825IdelalisibOne source FDA
- DrugBank DB09054One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C552946 | idelalisib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | YG57I8T5M0 | IDELALISIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1544460 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5908266 | idelalisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78825 | Idelalisib | One source FDA |
| DrugBank | DB09054 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.